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Abstract
Background: High-resolution oligo-SNP array allowed the identification of extremely small pathogenic deletions
at numerous clinically relevant regions. In our clinical practice, we found that small pathogenic deletions were
frequently encountered at chromosome 9p and 9q terminal regions.
Results: A review of 531 cases with reportable copy number changes on chromosome 9 revealed142 pathogenic
copy number variants (CNVs): 104 losses, 31 gains, 7 complex chromosomal rearrangements. Of 104 pathogenic
losses, 57 were less than 1 Mb in size, enriched at 9p24.3 and 9q34.3 regions, involving the DOCK8, KANK1, EHMT1
genes. The remaining 47 cases were due to interstitial or terminal deletions larger than 1 Mb or unbalanced
translocations. The small pathogenic deletions of DOCK8, KANK1 and EHMT1 genes were more prevalent than small
pathogenic deletions of NRXN1, DMD, SHANK3 genes and were only second to the 16p11.2 deletion syndrome,
593-kb (OMIM #611913).
Conclusions: This study corroborated comprehensive genotype-phenotype large scale studies at 9p24.3 and 9q24.3 regions
for a better understanding of the pathogenicity caused by haploinsufficiency of the DOCK8, KANK1 and EHMT1 genes.
Trial registration number: None; it is not a clinical trial, and the cases were retrospectively collected and analyzed.
Keywords: Small pathogenic deletions, High resolution oligonucleotide-single nucleotide polymorphism array analysis,
Haploinsufficiency, Homozygous deletions
Background
Chromosomal microarray analysis (CMA) has been
widely utilized for the genome-wide screening of micro-
deletion and microduplication syndromes [1]. The sizes
of well-known microdeletion and microduplication syn-
dromes were usually larger than 1 Mb, such as 1.4 Mb
for Williams-Beuren syndrome (OMIM #194050) or
2.8 Mb for DiGeorge syndrome (OMIM #188400). Small
(<1 Mb) pathogenic deletions at regions which were not
well characterized were frequently encountered during
our daily clinical practice, for instance, the chromosomal
regions at 9p24.3 and 9q34.3.
High-resolution oligo-SNP array is able to reveal a
variety of chromosomal disorders including uniparental
disomy or extremely small pathogenic deletions which
would be missed by low-resolution oligonucleotide
CMA. Our and other previous studies showed the cases
with uniparental disomy were relatively limited in num-
ber on chromosome 9 as compared to chromosome 15,
11 and 7 [2, 3]. In contrast, small pathogenic deletions
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were frequently encountered at chromosome 9p24.3 and
9q34.3 by using high-resolution oligo-SNP array in post-
natal studies. Research endeavors have been significantly
prioritized to specific genes such as NRXN1 and
SHANK3 in the past [4, 5]. To the best of our know-
ledge, only four cases with small deletions of 192 kb,
225 kb, 465 kb and 518 kb in size at 9p24.3 involving
the DOCK8 and/or KANK1 gene [6–8], and a case of
40 kb deletion in the EHMT1 gene at 9q34.3 [9] have
been documented.
The purpose of this study is to evaluate 1): the inci-
dence of small (< 1 Mb) pathogenic deletions in postna-
tal specimens, 2): whether the small pathogenic
deletions at 9p24.3 and 9q34.3 constituted a significant
proportion of small deletions, 3): what proportion of de-
letions on chromosome 9 was caused by small patho-
genic deletions at 9p24.3 and 9q34.3, 4): the efficacy of
identifying extremely small homozygous pathogenic de-
letions using high-resolution oligo-SNP array.
Results
The incidence of small pathogenic deletions in postnatal
specimens studied by high-resolution oligo-SNP array
Approximately 38,000 postnatal specimens were studied by
high-resolution oligo-SNP array in our laboratory from
2011 through 2015. Of these, we reported approximately
13,000 (34 %) pathogenic variants or variants of uncertain
clinical significance (VOUS). The detection rate was con-
sistent with our previous study [2]. Of the 13,000 variants,
a total of 373 recurrent (at least 3 cases) small pathogenic
losses were identified (Fig. 1). The 16p11.2 deletion syn-
drome, 593-kb (OMIM #611913) is the most common
small pathogenic loss (107 cases). The remaining involved
NRXN1 (35 cases), DMD (31 cases), DOCK8 and/or
KANK1 (30 cases), and other chromosomal regions such
as 16p11.2 (OMIM #613444, 220-KB), 16p12.2 (OMIM
#136570, 520-KB), 22q13.33 (OMIM #606232).
Approximately 12 % of the recurrent small pathogenic
copy number losses were caused by deletions of DOCK8
andKANK1 at 9p24.3 and EHMT1 at 9q34.3
The total number of deletions involving DOCK8
and/or KANK1 genes at 9p24.3 (30 cases, Fig. 2) and
EHMT1 gene at 9q34.3 (16 cases, Fig. 3a) consti-
tuted approximately 12 % (46/373 cases) of the re-
current small pathogenic deletions from all the
chromosomes.
Small (<1 Mb) and relatively small (1–1.5 Mb) deletions
constituted 59 % of pathogenic copy number losses on
chromosome 9
Of 13,000 cases with reported copy number variants
(CNVs), 531 cases were from chromosome 9, and 142
were pathogenic, including 104 losses, 31 gains, 7 com-
plex chromosomal rearrangements with both losses and
gains (Table 1 and Additional file 1: Figure S1). Of 104
pathogenic losses, 57 were smaller than 1 Mb in size. Of
57 cases, 46 were located at 9p24.3 and 9q34.3 regions,
involving the DOCK8, KANK1, EHMT1 genes. The size
ranged from 22 kb (case 54 with EHMT1 deletion) to
Fig. 1 The recurrent small pathogenic small copy number losses from all the chromosomes. The small pathogenic deletions on chromosome 9,
involving DOCK8, KANK1, EHMT1 genes constituted a significant proportion (12 %) of cases
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790 kb (case 35), with an average of 384 kb (Table 1 and
Additional file 2: Table S1). The remaining 47 cases were
either resulted from interstitial deletions over 1 Mb in
size (18 cases), terminal deletions over 1 Mb (14 cases),
or unbalanced translocations (15 cases) that could be as
small as 880 kb in size in a t(9;11)(q34.3;p15.4)(case 47,
Additional file 2: Table S2). Very interestingly, of these
47 cases, four had relatively small deletions (1–1.5 Mb
in size): a 1,048-kb deletion (case 10, Additional file 2:
Table S2) involving the PTCH1 gene (OMIM 601309)
and diagnosis of Gorlin syndrome (OMIM #109400),
a 1,349-kb deletion (case 15) involving the STXBP1
gene and diagnosis of early infantile epileptic enceph-
alopathy (OMIM #612164), and two 9q34.3 deletions
of 1,218 kb and 1,268 kb (case 31 and 32). The small
(57 cases) and relative small (4 cases) deletions
established 59 % (61/104) of pathogenic copy number
losses on chromosome 9.
The 9p24.3 (0–2.2 Mb from 9p telomere) and 9q34.3
(137.4–141.2 Mb from 9p telomere) were two hot spots
of pathogenic copy number losses on chromosome 9
The 9p24.3 and 9q34.3 regions were two hot spots of
copy number losses on chromosome 9. A total of 35
cases majorly involved the 9p24.3 region: 30 small
pathogenic deletions (case 1–30, Additional file 2: Table
S1), one interstitial deletion (case 1, Additional file 2:
Table S2), two terminal deletions (case 19 and 20), and
two unbalanced translocations (case 33 and 35). Add-
itionally, 26 cases were localized to 9q34.3 region: 17
small pathogenic deletions (case 41–57, Additional file 2:
Table S1), one interstitial deletion (case 18, Additional file 2:
Fig. 2 The distribution of deletions in cases with involvement of the DOCK8 and KANK1 genes. The copy number variants in the database of genomic
variation were compared to the profile of small deletions in our cohort. Segmental duplications were not flanking the deletions of the DOCK8 and
KANK1 genes, which potentially excluded the pathogenic mechanism through non-homologous recombination of segmental duplications
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Table S2), 5 large terminal deletions (case 28–32) and 3
unbalanced translocations (case 45–47). Overall, close to
60 % (61/104, 59 %) of deletions were localized to the very
ends of chromosome 9 at band 9p24.3 and 9q34.3.
Rarely encountered extremely small homozygous
pathogenic deletions were discovered in two cases
Extremely small homozygous pathogenic deletions were
identified in two cases: 1): a new born baby girl who pre-
sented with a metabolic disorder (abnormal reflexes,
hypotonia, seizures, and elevated glycine) was revealed
to contain a 25-kb homozygous deletion in the GLDC
gene, which gave rise to autosomal recessive glycine
encephalopathy (nonketotic hyperglycinemia; OMIM
#605899). Besides that, a 50-kb heterozygous deletion
was also found in the 5′ region of the GLDC gene. Par-
ental study showed the mother was a carrier of a 25-kb
heterozygous deletion and the father was a carrier of a
75-kb heterozygous deletion of the GLDC gene. The
25-kb maternally inherited deletion was located within the
75-kb paternally inherited deletion, and therefore inherit-
ance of abnormal allele from both parents led to a 25-kb
homozygous and a 50-kb heterozygous deletion in the pro-
band (Fig. 4); 2): a 1-year-old boy was found to have a 74-
kb homozygous deletion of the CDK5RAP2 gene in a re-
gion of homozygosity (Additional file 3: Figure S2) which
Fig. 3 a The genomic locations of the 16 small (<1 Mb) pathogenic deletions involving the EHMT1 gene. b. A 22-kb deletion (chr9:140,667,619-140,689,934)
was found in 32-year-old female with intellectual disability. c A 40-kb deletion (chr9:140,694,541-140,734,178) was identified in a 5-year-old girl. d A
39-kb deletion (chr9:140,650,471-140,689,373) was discovered in a 1-year-old girl with developmental delay, speech and motor delay, white matter
changes on MRI, and hypotonia
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led to autosomal recessive primary microcephaly-3
(OMIM #604804). The presence of multiple large regions
of homozygosity (a total of 421 Mb) implied these two par-
ents were closely related in blood. The proband inherited
the heterozygous abnormal allele with deletion of the
CDK5RAP2 gene from both parents.
Discussion
The subtelomeric region such as 1p36 is known to be
gene-rich and prone to have deletions, supported by a
study with a large cohort of over 5,000 cases [10]. The
cases with subtelomeric rearrangements comprised of
about 46 % of all the genomic abnormalities identified
by CMA [10]. However, as compared to 1p36, 22q13,
4p16, 5p15, very limited cases at the ends of chromosome
9p and 9q were established [10]. When we reviewed the
profile of copy number losses from our database of 38,000
postnatal cases studied by using high-resolution oligo-
SNP array and sorted it based on chromosomal regions,
we discovered that all the cases with 1p36 deletions were
over 1 Mb: 20 cases were 1–3 Mb, eight cases were 3–
5 Mb, eight cases were 5–10 Mb and five cases were 10–
Table 1 Profile of pathogenic copy number losses and gains in chromosome 9
Type or gene involved Number Mean, kb Range, kb
Copy number losses : large
Interstitial deletion 18 5,070 1,048–16,837
Terminal deletion 14 5,273 1,218–13,593
Unbalanced translocation 15 7,053 880–17,107
Subtotal 47
Copy number losses: small
DOCK8 24 299 97–431
KANK1 3 369 184–670
DOCK8 and KANK1 3 419 75–676
EHMT1 16 417 22–790
ASTN2 4 150 78–271
FREM1 2 369 166–573
STXBP1 1 592 NA
COL5A1 1 370 NA
GLDC 1 50 25–75
TOPORS 1 337 NA
CDK5RAP2 1 74 NA
Subtotal 57
Large copy number gains
Trisomy 9p/proximal 9q 15 45,996 13,826–95,453
9q duplications 6 12,172 6,277–18,399
Unbalanced translocation 4 25,717 6,794–68,089
Tetrasomy 9q and proximal 9q due to isochromosome 3 66,477 49,843–81,113
Trisomy 9 2 140,833 NA
Triplication 1 15,972 NA
Subtotal 31
Complex chromosomal rearrangements (CCRs)
Inverted duplication with terminal deletion of 9p 3 Deletion: 6,377; Duplication: 32,271
Inverted duplication with terminal deletion of 9q 1 Deletion: 161; Duplication: 3,127
Multiple deletion and duplication 2 Losses: 1091; Gains: 12,517
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20 Mb in size (unpublished data). In contrast, 61 of 104
pathogenic deletions on chromosome 9 were either smaller
than 1 Mb (57 cases) or between 1 and 1.5 Mb (4 cases).
This finding demonstrated that the size of copy number
losses conspicuously varied between chromosomal regions.
In the clinical practice, the concept of vigilant selecting ap-
propriate methods to characterize the genomic losses at dif-
ferent regions becomes essentially important. For instance,
FISH analysis using subtelomeric or locus-specific probe
may be approriate to identify 1p36 microdeletions, but may
miss cases with small deletions on chromosome 9.
Extremely small intragenic deletion of the EHMT1
gene was only reported in one case: a 40-kb intragenic
deletion of the EHMT1 gene with uncertain phenotypic
consequence [9]. A more recent update on Kleefstra
syndrome exhibited that the 16 newly diagnosed 9q34.3
deletions were all larger than 200 kb [11]. In our cohort,
we identified a total of 24 cases with 9q34.3 deletions:
16 with small (<1 Mb) deletions involving the EHMT1
gene (case 42–57, Additional file 2: Table S1), 5 with ter-
minal deletion of 9q (case 28–32, Additional file 2: Table
S2), and 3 with small (880–1001 kb in size) 9q34.3 dele-
tions due to unbalanced translocations (case 45–47,
Additional file 2: Table S2). Remarkably, we brought about
three extremely small (22 kb, 39 kb and 40 kb in size) in-
tragenic deletions of the EHMT1 gene and all were clus-
tered at the 3′ end of the gene (Fig. 3, b-d). The 22-kb
deletion (Fig. 3b) was identified in a 32-year-old female
with intellectual disability; whereas, the 40-kb deletion
(Fig. 3c) was found in a 5-year-old girl and the 39-kb dele-
tion (Fig. 3d) was discovered in a 1-year-old girl with typical
features of 9q34.3 deletion including developmental delay,
speech and motor delay, and hypotonia [9]. In addition, a
26-year-old male with a 165-kb deletion involving EHMT1
and CACNA1B gene (case 57, Additional file 2: Table S1)
also presented clinical features which were typical for
9q34.3 deletion syndromes including mental retardation,
developmental delay, speech delay, motor delay, learning
disability, autism spectrum disorder, asymmetry of temporal
lobe, localized polymicrogyria, loping gait and scoliosis [11].
In contrast to the EHMT1 gene of which haploinsuffi-
ciency score was much better established by ClinGen
Fig. 4 Family study of homozygous and heterozygous deletion of the GLDC gene. High-resolution oligo-SNP array analysis of the proband re-
vealed a 25-kb homozygous and a 50-kb heterozygous deletion at the 5′ region of the GLDC gene. These two deletions involved multiple exons
and led to autosomal recessive glycine encephalopathy (nonketotic hyperglycinemia; OMIM #605899). Family study showed the mother was a car-
rier of a 25-kb heterozygous deletion and the father was a carrier of a 75-kb heterozygous deletion of the GLDC gene. The 25-kb maternally inher-
ited deletion was located within the 75-kb paternally inherited deletion, and thus led to a 25-kb homozygous and a 50-kb heterozygous deletion
in the proband
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(https://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/
), the sensitivity to haploinsufficiency for DOCK8 and
KANK1 genes was not proven (Additional file 2: Table
S3). There were two unrelated patients with mental re-
tardation and developmental disability (MRD2; OMIM
#614113) who were disclosed to have a heterozygous dis-
ruption of the longest isoform of the DOCK8 gene by ei-
ther deletion or a translocation of t(X;9) [12]. A recent
report of another two patients with almost identical deletion
involving both DOCK8 and KANK1 displayed two distinct
phenotypes [6]. The study of a four-generation with a 225-
kb deletion of the KANK1 gene implied that an imprinting
mechanism may play a role in the phenotypic variation in
this family. The authors suggested KANK1 is a maternally
imprinted gene and only expressed in the paternal allele [8].
However, other report did not support this finding [7]. In
our cohort, deletions of KANK1 were found in 6 cases (case
25–30, Additional file 2: Table S1). There were not enough
clinical data to determine whether KANK1 is a maternally
imprinted gene. On the other hand, DOCK8 gene is unlikely
to be maternally imprinted since the two half-brothers (a 2-
year-old boy and a 7-year-old boy, case 13 and 14, Add-
itional file 2: Table S1) both inherited the deleted DOCK8
allele from the same mother. In addition, our patients with
small deletions of the DOCK8 gene had very strong family
history (case 13/14, 17, 20/21 Additional file 2: Table S1)
and shared similar clinical features, including developmental
delay and intellectual disability (4 out of 5 cases), speech
and motor delay (3), learning disability (2), behavior prob-
lems or autism (3), macrocephaly (2), dysmorphic or con-
genital anomalies (4). Our cohort provided additional
pathogenic evidence for haploinsufficiency of DOCK8 gene.
Although extremely rare, two cases with homozygous
deletions of GLDC and CDK5RAP2 genes were discov-
ered in this cohort. In our previous study, we demon-
strated the autosomal recessive disorders could be
linked to regions of homozygosity (ROH) containing
gene with point mutation which was inherited from re-
lated parents [2]. In this study, we showed additional
two cases with autosomal recessive disorders which can
be identified by high-resolution oligo-SNP array. The
first was due to inheritance of allele with heterozygous
deletion of different size from each carrier parent, which
led to a homozygous deletion of GLDC gene (Fig. 4). The
second was a homozygous deletion of the CDK5RAP2
gene, inherited from closely related parents who carried
the same heterozygous deletion (Additional file 3: Fig-
ure S2A). These two cases proved the efficacy of using
high-resolution oligo-SNP array in the identification of
extremely small homozygous pathogenic deletions.
Conclusions
This study demonstrated 1): the incidence of recurrent
small pathogenic deletions (< 1 Mb) was approximately
3 % (373/13,000) of all reported CNVs; 2): the small
pathogenic deletions at 9p24.3 and 9q34.3 constituted
12 % of small pathogenic deletions from all the chromo-
somes, 3): 59 % of pathogenic deletions on chromosome
9 were due to small (<1 Mb) or relatively small (1–
1.5 Mb) pathogenic deletions; 4): 81 % (46/57) of small
pathogenic deletions were enriched at 9p24.3 and 9q34.3
regions involving the DOCK8, KANK1 and EHMT1
genes; 5): high-resolution oligo-SNP array was capable of
identifying homozygous deletions as small as 25 kb in size.
Methods
Patients
Patients with a broad range of clinical indications includ-
ing intellectual disability, developmental delay, multiple
congenital anomalies, dysmorphic features and pervasive
developmental disorders were referred to our laboratory
for oligo-SNP array studies. The data for this study were
compiled from de-identified results of 38,000 consecutive
patient specimens referred to our laboratory for constitu-
tional oligo-SNP array study from 2011 to 2015. The pa-
tients were majorly from general population in the United
States, with < 5 % from Mexico and other countries.
Oligonucleotide-single nucleotide polymorphism array
analysis platforms and threshold setting
Oligo-SNP array analysis was performed on either
Human SNP Array 6.0 (in 2011) or CytoScan® HD
(2012–2015)(Affymetrix, Santa Clara, CA), using gen-
omic DNA extracted from whole blood. The Human
SNP Array 6.0 has 1.8 million genetic markers, including
about 906,600 SNPs and 946,000 probes for the detec-
tion of CNVs. The CytoScan® HD has more than 2.67
million probes, including 1.9 million non-polymorphic
copy number probes and 750,000 SNP probes. The over-
all resolutions are approximately 1.7 kb for Human SNP
Array 6.0 and 1.15 kb for CytoScan® HD. For chromosome
9, the probes for Human SNP Array 6.0 covered:
9p(chr9:37,747-47,217,164) and 9q(chr9:65,596,318-
141,091,382); for CytoScan HD®: 9p (chr9:192,129-
40,784,142, chr9:43,400,082-44,900,526) and 9q (chr9:66,
837,485-141,025,328). Genomic coordinates were based
upon genome build 37/hg19 (2009). Hybridization, data
extraction, and analysis were performed as per manufac-
turers’ protocols. The Affymetrix® Chromosome Analysis
Suite (ChAS) Software version 2.0 was used for data ana-
lysis, review, and reporting. For genome-wide screening,
thresholds were set at > 200 kb for gains and > 50 kb for
losses. For cytogenetically relevant regions, thresholds
were set at > 100 kb for gains and > 20 kb for losses.
Benign CNVs that are documented in the database of
genomic variations (http://dgv.tcag.ca/dgv/app/home?-
ref=GRCh37/hg19) and present in the general population
were excluded from reporting.
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Additional files
Additional file 1: Figure S1. Profile of abnormal CNVs and VOUS in
chromosome 9 from 531 cases. A total of 142 cases with pathogenic
CNVs, and 389 cases with VOUS were identified. (JPG 52 kb)
Additional file 2: Table S1. List of the cases with small (<1 Mb)
pathogenic copy number loss on chromosome 9 without involvement of
other chromosomes (N = 57). Table S2. List of the remaining cases with
copy number loss on chromosome 9 (N = 47). Table S3. Interpretation,
references and ClinGen evaluation of haploinsufficiency score of selected
cytogenetically relevant genes on chromosome 9. (DOCX 43 kb)
Additional file 3: Figure S2. A. The finding of multiple large regions of
homozygosity (421 Mb) was due to closely parental relatedness. B. An
approximately 74-kb homozygous deletion involved multiple exons of
the CDK5RAP2 gene in a region of homozygosity at 9q33.1-q34.11
(chr9:118,503,864-132,425,233), which caused autosomal recessive primary
microcephaly-3 (OMIM #604804). (JPG 60 kb)
Abbreviations
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FISH: Fluorescence in situ hybridization; ISCN: International System of
Cytogenetic Nomenclature; Oligo-SNP array: Oligonucleotide-single
nucleotide polymorphism array; UPD: Uniparental disomy; VOUS: Variants of
uncertain clinical significance
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